Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Hookipa Pharma Inc
(NQ:
HOOK
)
5.260
+0.050 (+0.96%)
Streaming Delayed Price
Updated: 10:12 AM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Hookipa Pharma Inc
< Previous
1
2
Next >
HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
June 10, 2023
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma Announces Pricing of $50.0 Million Public Offering of Common Stock and Non-Voting Convertible Preferred Stock
May 31, 2023
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma Announces Positive Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab in Patients with HPV16+ Head and Neck Cancers
May 31, 2023
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma Reports First Quarter 2023 Financial Results and Recent Business Highlights
May 11, 2023
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Announces First Person Dosed in Phase 1a/b Clinical Trial of HB-400, in Collaboration with Gilead, for Treatment of Hepatitis B
May 09, 2023
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma to Participate in Upcoming Investor Conferences in May
May 04, 2023
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 11, 2023
May 04, 2023
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA to Present a Trial in Progress Poster on its Prostate Cancer Phase 1/2 Clinical Trial at ASCO
April 26, 2023
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma to Participate in the Van Lanschot Kempen Life Sciences Conference
April 19, 2023
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
April 14, 2023
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Outlook
March 15, 2023
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma Appoints Terry Coelho to its Board of Directors
March 13, 2023
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma to Report Fourth Quarter and Full Year 2022 Financial Results and Provide a Corporate Update on March 15, 2023
March 08, 2023
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Achieves $10 Million Milestone Payment in Development of Immunotherapy for KRAS-Mutated Cancers
February 13, 2023
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA to Present at the SVB Securities Global Biopharma Conference
February 07, 2023
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma Achieves $5 Million Milestone Payment from Gilead Sciences for Progress in the Development of Hepatitis B Vaccine
January 04, 2023
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma Appoints Katia Schlienger, M.D., Ph.D., Chief Medical Officer and Malte Peters, M.D., to Board of Directors
December 15, 2022
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA to Participate in The JMP Securities Hematology and Oncology Summit
November 30, 2022
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma Announces Third Quarter 2022 Financial Results and Provides a Business Update
November 14, 2022
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
Sidoti's November Micro-Cap Virtual Conference
November 08, 2022
Via
ACCESSWIRE
HOOKIPA Pharma to Report Third Quarter 2022 Financial Results and Corporate Updates on November 14, 2022
November 07, 2022
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA to Participate in the Sidoti Micro-Cap Virtual Conference
November 02, 2022
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
HOOKIPA Pharma (NASDAQ: HOOK) Enters into Collaboration Deal with Roche to Develop HB-700 For KRAS-Mutated Cancers
October 20, 2022
HOOKIPA Pharma, Inc. (NASDAQ: HOOK) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research and development
Via
Spotlight Growth
HOOKIPA announces strategic collaboration and license agreement with Roche to develop novel arenaviral immunotherapy for KRAS-mutated cancers
October 20, 2022
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.